300,000 Gilead Sciences, Inc. $GILD Shares Sold by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 49.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 304,000 shares of the biopharmaceutical company’s stock after selling 300,000 shares during the period. Migdal Insurance & Financial Holdings Ltd.’s holdings in Gilead Sciences were worth $45,311,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Gilead Sciences in the 2nd quarter worth $15,393,785,000. State Street Corp grew its position in shares of Gilead Sciences by 2.3% during the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after acquiring an additional 1,357,967 shares during the period. Amundi increased its position in Gilead Sciences by 10.7% in the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after buying an additional 1,018,976 shares during the last quarter. Legal & General Group Plc purchased a new stake in Gilead Sciences in the 2nd quarter worth about $1,316,606,000. Finally, Deutsche Bank AG purchased a new position in shares of Gilead Sciences in the second quarter worth about $918,387,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In related news, Director Anthony Welters sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director directly owned 12,894 shares of the company’s stock, valued at $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Wettan Keeley M. Cain sold 3,399 shares of the business’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $164.11, for a total value of $557,809.89. Following the transaction, the executive vice president owned 5,360 shares in the company, valued at approximately $879,629.60. This represents a 38.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 242,709 shares of company stock valued at $39,503,427. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 0.1%

Shares of NASDAQ GILD traded up $0.13 during mid-day trading on Friday, hitting $168.08. The stock had a trading volume of 3,637,311 shares, compared to its average volume of 6,772,945. The business has a 50 day moving average price of $155.10 and a two-hundred day moving average price of $141.80. Gilead Sciences, Inc. has a 1 year low of $116.88 and a 1 year high of $176.58. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. The firm has a market cap of $208.48 billion, a P/E ratio of -53.19 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.47 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post -0.98 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is -103.80%.

Latest Gilead Sciences News

These are some of the GILD news items that stood out recently:

• Positive Sentiment: Zacks Research raised several forecasts, including FY2027 EPS to $9.42 from $9.36 and FY2028 EPS to $9.69 from $9.66. It also made small upward adjustments to quarterly estimates. The revisions suggest slightly improved expectations, though the analyst’s Hold rating tempers the signal.
• Positive Sentiment: Coverage points to momentum in Gilead’s HIV franchise: Yeztugo sales are described as surging, Biktarvy remains a market leader, and the expanding pipeline could support longer-term growth. Read More..
• Neutral Sentiment: Gilead announced a partnership with TelevisaUnivision to promote HIV-prevention awareness at the Latin GRAMMY Awards. It may build awareness, but the announcement does not specify a direct near-term financial impact. Read More..

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on GILD. Citigroup lifted their price target on Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Truist Financial increased their price target on shares of Gilead Sciences from $158.00 to $181.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Barclays decreased their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Finally, Scotiabank upped their price target on shares of Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a research report on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $171.07.

Gilead Sciences Profile

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.